Keith Regnante
Known title: Chief Financial OfficerCIK: 0001682068
Associated companies
Transaction History
| KROS | ▼ Sell | Open Market | 4,739 | $77K | 2/18/2026 | View on chart |
| KROS | ▲ Buy | Grant | 44,000 | $0 | 2/18/2025 | View on chart |
| KROS | ▲ Buy | Option Exercise | 40,000 | $640K | 11/4/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 40,000 | $1.8M | 11/4/2023 | View on chart |
| KROS | ▲ Buy | Option Exercise | 20,000 | $320K | 6/9/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 15,993 | $720K | 6/9/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 1,428 | $66K | 6/9/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 2,579 | $122K | 6/9/2023 | View on chart |
| KROS | ▲ Buy | Option Exercise | 20,000 | $320K | 6/8/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 17,301 | $825K | 6/8/2023 | View on chart |
| KROS | ▼ Sell | Open Market | 2,699 | $131K | 6/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.